Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival

Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, United Kingdom.
International Journal of Cancer (Impact Factor: 5.09). 11/2008; 123(10):2247-53. DOI: 10.1002/ijc.23851
Source: PubMed


The tumour suppressor gene (TSG) LIM domain containing protein 1 (LIMD1) has been associated with transformation of epithelial cells of the lung and its expression is downregulated in all lung tumour samples tested compared to normal lung matched controls. In the first study of its kind we used an anti-LIMD1 specific monoclonal antibody to investigate expression/localisation of the LIMD1 protein in a well-characterised tissue microarray of breast cancers and normal adjacent epithelia. Comparison of tumour with adjacent normal and distant normal tissue demonstrated that LIMD1 expression is moderate to high compared to tumour. There was also a significant correlation with histological grade (p = 0.0001), tumour size (p = 0.013) and tumour type (p = 0.004) indicating an association with aggressive disease. Cytoplasmic LIMD1 expression was seen in 99.3% of cases, with 43.1% showing both nuclear and cytoplasmic localisation. Absence/loss of nuclear staining showed a strong correlation with patient survival and was indicative of poor prognosis (p = 0.033). There was no association with lymph node status and other clinicopathological parameters. Nuclear staining was more pronounced in better prognosis tumours and normal tissue. This study demonstrates that LIMD1 represents a novel prognostic marker for breast cancer. Combined with the fact that LIMD1 expression is downregulated in lung cancers this clearly indicates that LIMD1 may represent a critical TSG, the function of which is deregulated via overall loss of expression and/or relocalisation within the cell during tumour development. The possible functions of LIMD1 localisation within the nucleus and cytoplasm and its relationship to tumour prognosis are discussed.

Download full-text


Available from: Ian Spendlove, Oct 14, 2014
13 Reads
  • Source
    • "locus with LIMD1 loss flagged as a possible cause of tumour formation [7]. A reduction in LIMD1 expression is also correlated with poor prognosis and survival rates in breast cancer [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: LIMD1 is a tumour suppressor gene (TSG) down regulated in ∼80% of lung cancers with loss also demonstrated in breast and head and neck squamous cell carcinomas. LIMD1 is also a candidate TSG in childhood acute lymphoblastic leukaemia. Mechanistically, LIMD1 interacts with pRB, repressing E2F-driven transcription as well as being a critical component of microRNA-mediated gene silencing. In this study we show a CpG island within the LIMD1 promoter contains a conserved binding motif for the transcription factor PU.1. Mutation of the PU.1 consensus reduced promoter driven transcription by 90%. ChIP and EMSA analysis demonstrated that PU.1 specifically binds to the LIMD1 promoter. siRNA depletion of PU.1 significantly reduced endogenous LIMD1 expression, demonstrating that PU.1 is a major transcriptional activator of LIMD1.
    FEBS letters 03/2011; 585(7):1089-96. DOI:10.1016/j.febslet.2011.03.013 · 3.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Classic designs of FSK demodulator generally employ conventional phase locked loop second order (PLL). In this paper, we explore the design of a new architecture (without using any filters) of high-performance integrated FSK demodulator using ISPD PLL (inverse sine phase detector PLL). This architecture has clearly shown superior frequency performances, such as large bandwidth, large keep range, large seizure range and a perfect reconstruction of an input signal, when compared to the conventional architecture. The digital design of the system involves the use of the SIMPLORER simulator for the hardware description language VHDL-AMS.
    Microelectronics, 2004. ICM 2004 Proceedings. The 16th International Conference on; 01/2005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Integrating signals from the ECM (extracellular matrix) via the cell surface into the nucleus is an essential feature of multicellular life and often malfunctions in cancer. To date many signal transducers known as shuttle proteins have been identified that act as both: a cytoskeletal and a signalling protein. Here, we highlight the interesting member of the Zyxin family TRIP6 [thyroid receptor interactor protein 6; also designated ZRP-1 (zyxin-related protein 1)] and review current literature to define its role in cell physiology and cancer. TRIP6 is a versatile scaffolding protein at FAs (focal adhesions) involved in cytoskeletal organization, coordinated cell migration and tissue invasion. Via its LIM and TDC domains TRIP6 interacts with different components of the LPA (lysophosphatidic acid), NF-κB (nuclear factor κB), glucocorticoid and AMPK (AMP-activated protein kinase) signalling pathway and thereby modulates their activity. Within the nucleus TRIP6 acts as a transcriptional cofactor regulating the transcriptional responses of these pathways. Moreover, intranuclear TRIP6 associates with proteins ensuring telomere protection and hence may contribute to genome stability. Accordingly, TRIP6 is engaged in key cellular processes such as cell proliferation, differentiation and survival. These diverse functions of TRIP6 are found to be dysregulated in various cancers and may have pleiotropic roles in tumour initiation, tumour growth and metastasis, which turn TRIP6 into an attractive candidate for cancer diagnosis and targeted therapy.
    Biology of the Cell 12/2011; 103(12):573-91. DOI:10.1042/BC20110077 · 3.51 Impact Factor
Show more